Provectus Biopharmaceuticals shares rally as Phase 2 trial data for PRV111 shows a 95.5% pathologic complete response rate in early-stage oral cancer patients.
Provectus Biopharmaceuticals has demonstrated significant clinical efficacy for its PRV111 candidate, with 21 out of 22 evaluable patients achieving a centrally confirmed pathologic complete response (pCR) after just one cycle. This 95.5% success rate in early-stage oral cancer provides a strong clinical validation for the company's proprietary platform and significantly de-risks the development pipeline for this specific indication.
The trial reported a 95.5% pathologic complete response rate, with 21 out of 22 evaluable patients achieving the result.
The patients achieved the centrally confirmed pathologic complete response following a single cycle of PRV111.
Provectus Biopharmaceuticals shares are in focus after the company announced a 95.5% pathologic complete response rate in its Phase 2 trial for PRV111. Twenty-one out of twenty-two evaluable patients with early-stage oral cancer achieved a centrally confirmed response following a single treatment cycle.
The trial demonstrated a high efficacy rate of 95.5% in achieving pathologic complete response for early-stage oral cancer patients, marking a significant milestone for the company's clinical pipeline.